GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Cyclically Adjusted Book per Share

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Cyclically Adjusted Book per Share : €0.00 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Laboratorios Farmaceuticos Rovi's adjusted book value per share for the three months ended in Mar. 2024 was €10.131. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Laboratorios Farmaceuticos Rovi's average Cyclically Adjusted Book Growth Rate was 16.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 18.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 15.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Laboratorios Farmaceuticos Rovi was 18.20% per year. The lowest was 15.10% per year. And the median was 15.60% per year.

As of today (2024-06-04), Laboratorios Farmaceuticos Rovi's current stock price is €88.75. Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €0.00. Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Laboratorios Farmaceuticos Rovi was 16.89. The lowest was 5.54. And the median was 8.34.


Laboratorios Farmaceuticos Rovi Cyclically Adjusted Book per Share Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Cyclically Adjusted Book per Share Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.55 3.86 4.67 5.49 6.37

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.75 5.97 6.20 6.37 -

Competitive Comparison of Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PB Ratio falls into.



Laboratorios Farmaceuticos Rovi Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Laboratorios Farmaceuticos Rovi's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=10.131/122.7621*122.7621
=10.131

Current CPI (Mar. 2024) = 122.7621.

Laboratorios Farmaceuticos Rovi Quarterly Data

Book Value per Share CPI Adj_Book
201406 3.030 101.081 3.680
201409 3.097 100.441 3.785
201412 3.189 100.251 3.905
201503 3.323 99.474 4.101
201506 3.225 101.138 3.915
201509 3.285 99.559 4.051
201512 3.341 100.268 4.091
201603 3.527 98.638 4.390
201606 3.560 100.333 4.356
201609 3.632 99.737 4.470
201612 3.722 101.842 4.487
201703 3.856 100.896 4.692
201706 3.855 101.848 4.647
201709 3.882 101.524 4.694
201712 3.887 102.975 4.634
201803 4.027 102.122 4.841
201806 3.916 104.165 4.615
201809 4.079 103.818 4.823
201812 5.191 104.193 6.116
201903 5.317 103.488 6.307
201906 5.404 104.612 6.342
201909 5.666 103.905 6.694
201912 5.821 105.015 6.805
202003 6.071 103.469 7.203
202006 6.359 104.254 7.488
202009 6.670 103.521 7.910
202012 6.746 104.456 7.928
202103 7.173 104.857 8.398
202106 7.290 107.102 8.356
202109 8.182 107.669 9.329
202112 8.592 111.298 9.477
202203 7.894 115.153 8.416
202206 7.476 118.044 7.775
202209 8.611 117.221 9.018
202212 9.929 117.650 10.360
202303 10.832 118.948 11.179
202306 9.680 120.278 9.880
202309 10.404 121.343 10.526
202312 10.409 121.300 10.534
202403 10.131 122.762 10.131

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Laboratorios Farmaceuticos Rovi was 16.89. The lowest was 5.54. And the median was 8.34.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Laboratorios Farmaceuticos Rovi Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.